June 4, 2025 11:22 AM EDT
R&D

Anap­tys­Bio de­scribes ‘JAK-like’ ef­fi­ca­cy for PD-1 drug in rheuma­toid arthri­tis

Nicole DeFeudis

Editor

Anap­tys­Bio is claim­ing suc­cess with longer fol­low-up da­ta from a Phase 2b tri­al in rheuma­toid arthri­tis as it looks for a part­ner to take its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Oma­da Health is go­ing pub­lic on Fri­day at a $1.1B val­u­a­tion

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times